Natera, Inc. (NTRA)
USD 130.81
(-5.39%)
USD 130.81
(-5.39%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -446.24 Million USD | 18.02% |
| 2022 | -541.04 Million USD | -15.56% |
| 2021 | -468.17 Million USD | -116.47% |
| 2020 | -216.27 Million USD | -65.51% |
| 2019 | -130.67 Million USD | -14.0% |
| 2018 | -114.62 Million USD | 14.47% |
| 2017 | -134.02 Million USD | -38.91% |
| 2016 | -96.48 Million USD | -61.25% |
| 2015 | -59.83 Million USD | -9098.2% |
| 2014 | 665 Thousand USD | 102.63% |
| 2013 | -25.26 Million USD | -31.5% |
| 2012 | -19.21 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -74.31 Million USD | 12.09% |
| 2024 Q2 | -43.9 Million USD | 40.92% |
| 2023 Q2 | -112.42 Million USD | 18.71% |
| 2023 Q1 | -138.3 Million USD | 2.45% |
| 2023 FY | -443.56 Million USD | 18.02% |
| 2023 Q4 | -84.53 Million USD | 23.83% |
| 2023 Q3 | -110.98 Million USD | 1.28% |
| 2022 Q2 | -143.08 Million USD | -4.34% |
| 2022 Q3 | -119.05 Million USD | 16.8% |
| 2022 Q4 | -141.77 Million USD | -19.08% |
| 2022 FY | -541.04 Million USD | -15.56% |
| 2022 Q1 | -137.13 Million USD | 1.82% |
| 2021 Q2 | -115.29 Million USD | -82.96% |
| 2021 Q4 | -139.66 Million USD | 7.01% |
| 2021 FY | -468.17 Million USD | -116.47% |
| 2021 Q3 | -150.19 Million USD | -30.27% |
| 2021 Q1 | -63.01 Million USD | 14.81% |
| 2020 Q3 | -55.77 Million USD | -7.97% |
| 2020 Q4 | -73.96 Million USD | -32.61% |
| 2020 FY | -216.27 Million USD | -65.51% |
| 2020 Q1 | -34.87 Million USD | -0.18% |
| 2020 Q2 | -51.66 Million USD | -48.14% |
| 2019 Q3 | -21.09 Million USD | 26.34% |
| 2019 FY | -130.67 Million USD | -14.0% |
| 2019 Q4 | -34.81 Million USD | -65.03% |
| 2019 Q1 | -31.74 Million USD | -6.79% |
| 2019 Q2 | -28.63 Million USD | 9.8% |
| 2018 Q1 | -30.51 Million USD | 32.06% |
| 2018 Q3 | -27.16 Million USD | 0.19% |
| 2018 Q4 | -29.72 Million USD | -9.43% |
| 2018 FY | -114.62 Million USD | 14.47% |
| 2018 Q2 | -27.21 Million USD | 10.81% |
| 2017 Q1 | -37.03 Million USD | 1.81% |
| 2017 Q4 | -44.91 Million USD | -79.36% |
| 2017 FY | -134.02 Million USD | -38.91% |
| 2017 Q3 | -25.04 Million USD | 7.38% |
| 2017 Q2 | -27.03 Million USD | 26.99% |
| 2016 Q1 | -9.6 Million USD | 44.63% |
| 2016 FY | -96.48 Million USD | -61.25% |
| 2016 Q4 | -37.71 Million USD | -41.49% |
| 2016 Q3 | -26.65 Million USD | -18.39% |
| 2016 Q2 | -22.51 Million USD | -134.41% |
| 2015 Q1 | -6.27 Million USD | -243.54% |
| 2015 Q3 | -20.74 Million USD | -34.06% |
| 2015 FY | -59.83 Million USD | -9098.2% |
| 2015 Q4 | -17.34 Million USD | 16.36% |
| 2015 Q2 | -15.47 Million USD | -146.49% |
| 2014 Q2 | -1.2 Million USD | 83.45% |
| 2014 Q3 | 4.77 Million USD | 496.6% |
| 2014 Q4 | 4.37 Million USD | -8.5% |
| 2014 FY | 665 Thousand USD | 102.63% |
| 2014 Q1 | -7.28 Million USD | -100.22% |
| 2013 Q4 | -3.63 Million USD | 17.21% |
| 2013 Q1 | -9.86 Million USD | 0.0% |
| 2013 FY | -25.26 Million USD | -31.5% |
| 2013 Q3 | -4.39 Million USD | 0.0% |
| 2012 FY | -19.21 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -358.359% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | -3974.073% |
| Aspira Women's Health Inc. | -18.85 Million USD | -2267.096% |
| Biodesix, Inc. | -41.34 Million USD | -979.399% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | -17105.701% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -5496.792% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | -5496.792% |
| Bionano Genomics, Inc. | -215.24 Million USD | -107.32% |
| CareDx, Inc | -101.9 Million USD | -337.924% |
| Check-Cap Ltd. | -19.28 Million USD | -2213.709% |
| Castle Biosciences, Inc. | -67.97 Million USD | -556.465% |
| DarioHealth Corp. | -56.18 Million USD | -694.186% |
| Exact Sciences Corporation | -215.01 Million USD | -107.544% |
| Fulgent Genetics, Inc. | -72.69 Million USD | -513.859% |
| Guardant Health, Inc. | -564.72 Million USD | 20.98% |
| ICON Public Limited Company | 956.15 Million USD | 146.671% |
| IDEXX Laboratories, Inc. | 1.09 Billion USD | 140.674% |
| Illumina, Inc. | -1.06 Billion USD | 58.256% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | -4239.565% |
| iSpecimen Inc. | -11.16 Million USD | -3895.264% |
| Standard BioTools Inc. | -76.6 Million USD | -482.565% |
| MDxHealth SA | -27.32 Million USD | -1532.982% |
| 23andMe Holding Co. | -321.35 Million USD | -38.863% |
| Medpace Holdings, Inc. | 336.82 Million USD | 232.486% |
| Myriad Genetics, Inc. | -123.7 Million USD | -260.748% |
| Mainz Biomed B.V. | -26.64 Million USD | -1574.799% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | -4141.576% |
| NeoGenomics, Inc. | -107.73 Million USD | -314.202% |
| Neogen Corporation | 58.66 Million USD | 860.692% |
| Inotiv, Inc. | -81.46 Million USD | -447.809% |
| OpGen, Inc. | -15.68 Million USD | -2744.412% |
| OPKO Health, Inc. | -157.02 Million USD | -184.194% |
| Psychemedics Corporation | -2.92 Million USD | -15177.131% |
| Prenetics Global Limited | -52.51 Million USD | -749.771% |
| Prenetics Global Limited | -52.51 Million USD | -749.771% |
| Precipio, Inc. | -7.62 Million USD | -5756.234% |
| Personalis, Inc. | -109.93 Million USD | -305.913% |
| RadNet, Inc. | 98.69 Million USD | 552.136% |
| Sera Prognostics, Inc. | -39.82 Million USD | -1020.627% |
| Sotera Health Company | 276.69 Million USD | 261.279% |
| Neuronetics, Inc. | -30.55 Million USD | -1360.513% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -10167.948% |
| Star Equity Holdings, Inc. | -4.34 Million USD | -10167.948% |
| Trinity Biotech plc | -27.04 Million USD | -1550.009% |
| T2 Biosystems, Inc. | -49.66 Million USD | -798.528% |
| Twist Bioscience Corporation | -220.83 Million USD | -102.075% |
| Exagen Inc. | -22.83 Million USD | -1854.044% |